Sonnest, Inc. is pre-clinical healthcare company developing Electrast™, a voltage-activated ultrasound imaging drug that circulates through the body in the inactive state (dark on ultrasound) and is selectively activated (turned on) in the myocardium. With Electrast™ doctors will be able to evaluate perfusion of the heart quickly and cost-effectively at the point of care without exposure to ionizing radiation or toxic dies. The technology was developed by a talented team of cardiologists and chemical engineers at Drexel University with grant funding from the Coulter-Drexel Program and the inventors partnered with a team of successful serial healthcare entrepreneurs who have worked together for over 15 years across multiple companies to form Sonnest.

The Owl Peak Labs mission is to save lives by delivering breakthrough imaging technology to detect early-stage colorectal cancer. Owl Peak Labs has harnessed thermal signaling and designed a system of capturing visual and thermal imaging interpreted through artificial intelligence to provide highly accurate information to physicians. We are committed to improving outcomes and increasing access for underserved patient populations, which is directly reflected in our team construction and mission to save lives. After completing our first study and achieving broad proof of principal data, we are excited to continue building the future of cancer detection.

Scriptulate has developed a software platform that facilitates safer, smarter, and more efficient prescribing of controlled substances. It reduces overprescribing, the root cause of the opioid crisis. Scriptulate's one-click compliance engine ensures that a doctor is compliant with state, CDC, and other regulations.

COO and Director of Organizational Development & Business Strategy- Initially responsible for cultural transformation and growth objectives for an operator of urgent care clinics, assumed role of COO after 3 months

Director of Sales (2014-2018) Responsible for leading 70-person sales team, executing the sales strategy and delivering annual sales plan for Halyard Health’s North American Interventional Pain medical devices unit. The Interventional Pain business unit began as a low growth/low focus business and has become the fastest growing highest margin business within HYH.

Associate Director, Global Strategic Marketing, Interventional Pain (2011-2014) Responsible for developing the global marketing plan as well as the long-term growth strategy including product development and business development efforts.Created exhaustive stakeholder engagement program that included clinical advisory boards, clinical research roadmap, medical society partnerships and product advisory forums resulting in increased customer collaboration and the publication of more than 25 clinical papers in a 2.5 year period.Led global business development efforts for the entire medical device portfolio.

Built a vascular access/fluid delivery medical device company with private equity financing, growing a single $30M venture into two acquisition targets that sold for over $300M. Managed and supported operations in multiple locations in the US and Mexico.